Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19389799 | 0.95 | CYP3A4 (0.35) | BRD4CYP3A4SMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL14433840 | 0.81 | KDM4E (0.41) | OPRM1 | |
| SCHEMBL21062113 | 0.74 | DGAT1 (0.36) | SMN1; SMN2OPRM1LMNA | |
| SCHEMBL25084407 | 0.74 | LMNA (0.36) | BRD4CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL25662335 | 0.73 | OPRM1 (0.31) | OPRM1OPRL1 | |
| SCHEMBL22533638 | 0.73 | FFAR3 (0.38) | OPRM1OPRL1 | |
| SCHEMBL19143997 | 0.73 | NPSR1 (0.42) | CYP3A4OPRM1LMNA | |
| SCHEMBL6470655 | 0.72 | BRD4 (0.35) | BRD4CYP3A4SMN1; SMN2OPRL1LMNA | |
| SCHEMBL23374707 | 0.71 | HDAC4 (0.36) | — | |
| SCHEMBL1050696 | 0.71 | PKM (0.31) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |